News

Lowe syndrome, a genetic disease, affects about 1 in 500,000 people in the general population.

According to the company, Stargardt disease is an orphan blindness disease that affects approximately 35,000 people in the United States.

RVO can significantly reduce vision-related quality of life, particularly in more severe cases.

The authors suggested genetic mutation may relax the body’s defences and allow harmful bacteria to reach the eye.

According to the company, 2,500 clinical and peer-reviewed studies that span 235 disease states have demonstrated the clinical utility of Optos technology.

The company will add Pravin U. Dugel, MD, as executive director, and add Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, PhD, MBBS, to its management team.

The treatment is a minimally invasive intravitreal injection that can be performed with a topical anesthetic.

A new initiative from Prevent Blindness will kick off to provide free educational resources on retinopathy of prematurity.

AI matched and outshone human specialists.

Researchers have found that the interactive release of anti-inflammatory drugs depend on the level of retinal degeneration. A customized treatment approach is expected to be developed to reduce patients’ inconvenience of having multiple shots.

A new study shows that much of an older person with visual impairment's physical activity is achieved at home. Improved home lighting can help increase those at-home activity rates.

The platform to streamline clinical decision workflows, management of teleophthalmology, referral decisions and patient management while improving clinic efficiencies.

Anthony Mai, MD, shared results from using the miCOR 700 device, which is a new device from Zeiss, for phacoemulsification cataract surgery at the EnVision Summit 2024. He spoke with Peg Achenbach, OD, FAAO, Executive Director/Global Ambassador Strategies, Ophthalmology and Optometry at MJH Life sciences, on location in Puerto Rico to share more about his presentation.

Rajendra Apte, MD, PhD, has received the Research to Prevent Blindness /American Macular Degeneration Foundation Catalyst Award for innovative research approaches in studying age-related macular degeneration.

Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.

New treatments for geographic atrophy coming down the pike has the potential to change eye care providers' approach to identifying and managing the disease.

The prevailing message is that physicians have “a long way to go” in the optimization of management and prevention of myopic vitreoretinal disease.

iCRx is set to release the One Minute Eye Exam in April, potentially changing the way ophthalmologists and optometrists conduct eye examinations for corrective lenses.

Sruthi Arepalli, MD, discusses the case of a patient with syphilis and sheds light on the complexities of diagnosing a masquerading syndrome.

Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.

The 2024 EnVision Summit will feature a brand-new Optometry Program, co-chaired by Danica Marrelli, OD, FAAO, AAO Dipl, and Cecelia Koetting, OD, FAAO, DipABO.

The free, online event will feature presentations from Rachel Huckfeldt, MD, PhD, and Rachelle Lin, OD.

Twelve-week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration.

According to a news release, the Redwood City, California, site will complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi.

Central retinal artery occlusion is characterized by painless, sudden vision loss in one eye, which may be a sign of an eye stroke.